Not long ago I came across a nifty piece of guidance from Huron Consulting. The subject: how pharmaceutical and life sciences companies can bravely soldier on with an effective compliance program after they exit a corporate integrity agreement.
The paper is only six pages long and worth a read when you have spare time. Even for businesses outside the pharma and life sciences sectors, the basic principles it articulates are just as useful, the lessons just as thought-provoking. (Corporate integrity agreements, deferred-prosecution settlements, consent decrees—they all have the same fundamentals for success, really.)
